Snowden Capital Advisors’s Avanos Medical AVNS Stock Holding History

Snowden Capital Advisors’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25	Closed	–	–	1106
2021 Q4	$0	Buy	+25	New	+$808	﹤0.01%	2040

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Snowden Capital Advisors's AVNS Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Avanos Medical (AVNS) in Q1 2022, closing a stake of 25 shares.

Snowden Capital Advisors first reported a position in AVNS in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 299 funds tracked by Wall St. Rank hold AVNS as of Q1 2022.

Snowden Capital Advisors reported no remaining Avanos Medical position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 25 Avanos Medical shares in Q1 2022.
Snowden Capital Advisors first reported a position in Avanos Medical in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Avanos Medical position peaked at $0 in Q4 2021.
299 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.